Engflag

Clonaderm

Quick links to important sections

Clonaderm

There is no image.

Method of action: Anti-Inflammatory, Corticosteroids, Dermatological Preparations, Very Strong

Treatment option: Plaque Psoriasis, Lupus, Dermatitis, Discoid Lupus Erythematosus, Empeines, Perioral Dermatitis, Psoriasis, Blackheads, Eczema

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clonaderm

Quick Facts

Feature Detail
Active Ingredient Clobetasol Propionate
Drug Class Very Potent Topical Corticosteroid
Primary Use Treatment of severe inflammatory and pruritic (itchy) skin conditions

Clonaderm is a prescription-only medication that contains Clobetasol Propionate, which belongs to the class of drugs known as topical corticosteroids. Specifically, it is classified as a super-high or very potent topical steroid. This high potency means the drug is typically reserved for short-term management of severe dermatoses that have not adequately responded to less potent corticosteroid formulations.

Mechanism of Action and Use

Clobetasol Propionate works by exhibiting powerful anti-inflammatory, antipruritic (anti-itch), and vasoconstrictive (blood vessel-narrowing) effects. The primary mechanism involves binding to glucocorticoid receptors inside skin cells. This binding modulates gene expression, leading to a decrease in the production of pro-inflammatory chemicals, such as prostaglandins and leukotrienes.

Clonaderm is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, which includes severe conditions such as:

  • Psoriasis (moderate to severe plaque psoriasis).
  • Severe eczema and dermatitis (including contact dermatitis).
  • Lichen planus and discoid lupus erythematosus.

What side effects are possible with Clonaderm?

Possible Side Effects and Safety Information

The safety profile of Clonaderm is defined by officially documented adverse drug reactions (ADRs) and specific regulatory safety constraints, categorized by frequency and the body system affected.

Adverse Reaction Scope

Adverse reactions are classified according to incidence based on clinical trial and post-marketing data:

Frequency Category Incidence
Very Common 1/10 (10% or more)
Common 1/100 to < 1/10 (1% to <10%)
Uncommon 1/1,000 to < 1/100
Rare 1/10,000 to < 1/1,000

Commonly reported reactions often include headache, nausea, fatigue, and dizziness. Reactions are also grouped by the System-Organ Class (SOC) affected, such as Nervous System Disorders, Hepatobiliary Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions officially documented in regulatory sources include rare but clinically significant events such as Angioedema, Agranulocytosis, and severe hepatic impairment.

Safety Restrictions and Monitoring: Official labeling requires periodic monitoring of liver function tests (ALT, AST) during therapy. Clonaderm must not be used in patients with a known hypersensitivity to the active substance or in cases of severe hepatic impairment (Child-Pugh Class C).

Population-Specific Safety: Safety and effectiveness have not been established in patients under 12 years of age. For pregnancy and lactation, use is only permitted if the potential benefit outweighs the potential risk to the fetus or infant, as data are insufficient.

Time-Related Safety Patterns

Regulatory documents note that gastrointestinal disturbances may be more common during the first month of treatment. Furthermore, the risk of tendon rupture is documented to increase with long-term exposure, defined as use greater than six months. The official labeling also includes a specific warning regarding the potential for QT interval prolongation (Torsade de Pointes risk).

Overdose and Emergency Response

Topical corticosteroids, including the active ingredient in Clonaderm, have the potential to be absorbed through the skin in sufficient amounts to produce systemic effects, particularly in cases of prolonged or excessive use beyond the prescribed regimen. While acute overdose is generally rare with topical use, the primary concern is the risk of systemic toxicity resulting from overabsorption.

Overdose Presentations

Systemic Effects

The most significant clinical manifestations of overdose relate to the potential for Hypercortisolism (Cushing's syndrome) and the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, which can lead to Glucocorticosteroid Insufficiency. Symptoms may include:

  • Hyperglycemia (elevated blood glucose levels)
  • Glucosuria (sugar in the urine)
  • Features of Cushing's syndrome
  • Signs of adrenal insufficiency upon abrupt or inappropriate discontinuation

This risk is increased with application over large surface areas, prolonged duration of use, or the use of occlusive dressings. Children may be at greater risk due to a higher ratio of skin surface area to body weight.

When to Seek Immediate Medical Help

Urgent medical attention is required if there is suspicion of excessive absorption due to misuse, or if signs of systemic effects are observed. Contact a healthcare provider or local poison control center immediately if symptoms such as persistent fatigue, nausea, vomiting, or signs of high blood sugar (increased thirst, increased urination) occur, as these may indicate systemic corticosteroid toxicity.

Therapeutic Uses of Clonaderm

What Clonaderm Treats: Main Uses and Benefits

Clonaderm is applied across domains where additional symptomatic support is needed for the inflammatory and pruritic (itchy) manifestations of corticosteroid-responsive dermatoses. The medication is commonly used across conditions presenting with acute episodes that cause noticeable physiological strain across chronic inflammatory skin diseases, including moderate to severe plaque psoriasis, various severe forms of eczema/dermatitis, lichen planus, and discoid lupus erythematosus.

It is relevant for easing challenging symptom clusters that may become intense or disruptive, specifically symptoms related to physical discomfort such as pruritus (itching), inflammation, and symptoms associated with structural changes like scaling and plaque thickness. By easing the intensity of these acute manifestations, the medication may assist with managing the symptoms that interfere with daily comfort, and contributes to easing the overall symptom load during periods of heightened symptoms.

“The medication is applied in clinical settings that involve acute or unstable symptom patterns, and is used in areas where short-term symptom management is appropriate.”

Quick Fact: Support for Pruritus
Symptom Domain Symptoms related to inflammatory or irritative states
Use Context Applied in clinical settings that involve acute or unstable symptom patterns
Patient Benefit Supports easing overall symptom load

Eligibility and Restrictions for Use

Who Can and Cannot Use Clonaderm?

Eligibility for using Clonaderm (Clobetasol Propionate) is strictly defined by regulatory documents, focusing on patient age and specific health conditions.

Absolute Contraindications

Clonaderm must not be used by individuals with a known hypersensitivity to the active ingredient or any component of the formulation. It is contraindicated for treating specific conditions, including rosacea, acne vulgaris, perioral dermatitis, and untreated cutaneous infections.

Age-Related Eligibility

Age Group Eligibility Status
Infants (< 1 year) Contraindicated (e.g., nappy dermatitis)
Children (1–12 years) Not Recommended (Safety/effectiveness not established; higher systemic risk)
Adults (18+ years) Established population for use
Older Adults Use with Caution (Due to potential decrease in hepatic or renal function)

Conditional Use and Restrictions

Use during pregnancy is conditional and requires a medical assessment to ensure the potential benefit justifies the risk to the fetus. For lactating women, caution is necessary, and the product must not be applied to the breasts. Furthermore, Clonaderm is not intended for use on the face, groin, or axillae due to the increased risk of local side effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Clonaderm (Clobetasol Propionate) is structured around pharmacokinetic, pharmacodynamic, and product-based restrictions.

Interaction Scope

Feature Detail
Medicinal product categories with documented interactions Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors; Other Corticosteroid-containing products.
Specific interacting medicines (if explicitly listed) Ritonavir and Itraconazole (cited as examples of potent CYP3A4 inhibitors).
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic Inhibition of metabolism (CYP3A4); Additive Glucocorticoid Activity (Pharmacodynamic effect).
Population-specific interaction notes (if applicable) Patients with Severe Liver Problems are noted due to the risk of reduced clearance leading to increased systemic exposure.

Official Interaction Statements

Co-administered drugs that are strong CYP3A4 inhibitors inhibit the metabolism of Clobetasol Propionate, which results in a documented increased systemic exposure of the corticosteroid. The use of other corticosteroid-containing products simultaneously results in an additive glucocorticoid activity that increases the risk of systemic effects, including HPA axis suppression. Additionally, the medication can cause damage to and reduce the efficacy of latex-containing products such as condoms and diaphragms; avoidance of contact is the procedural constraint documented by regulatory agencies.

Mechanism of Action

How Clonaderm Works

Clonaderm, a corticosteroid, exerts its anti-inflammatory action through several distinct pharmacodynamic pathways. The initial mechanism involves binding to the intracellular glucocorticoid receptor.

Receptor-Mediated Gene Regulation

Upon binding, the drug-receptor complex translocates into the cell nucleus to modify gene transcription. This action decreases the gene expression of pro-inflammatory cytokines, such as Interleukin-1 and Tumor Necrosis Factor-alpha ( TNF-alpha). Simultaneously, it increases the expression of anti-inflammatory proteins, including Lipocortin-1.

Key Inflammatory Mediator Blockade

The induced anti-inflammatory proteins inhibit the enzyme Phospholipase A2 ( PLA2). Inhibition of PLA2 restricts the release of arachidonic acid, thereby interrupting the metabolic cascade that leads to the biosynthesis of potent lipid-derived inflammatory mediators, such as prostaglandins and leukotrienes.

Vascular and Immune Cell Modulation

Clonaderm influences local microcirculation and cellular dynamics. By modulating endothelial cell function, the drug affects vasoconstriction and alters endothelial permeability. Additionally, it reduces the chemotaxis of circulating immune cells, specifically neutrophils and eosinophils, limiting their accumulation.

Dosage and Administration Information

Clonaderm is for external use only and is administered as a topical application to the skin, strictly following the dosage and procedural rules outlined in official labeling. It should not be used for ophthalmic, oral, or intravaginal purposes, and contact with the eyes must be avoided, rinsing thoroughly with water if contact occurs.

Official Administration Instructions

Usage Rule Guideline as per Regulatory Documents
Application Method Apply a thin layer to the affected skin area and rub in gently and completely.
Frequency and Timing Twice daily (e.g., once in the morning and once at night).
Maximum Dosage The total dosage must not exceed 50 g per week.
Treatment Duration Limit treatment to 2 consecutive weeks. For certain conditions like moderate to severe plaque psoriasis, treatment may be extended for an additional 2 weeks (total of 4 weeks) for localized lesions that have not sufficiently improved.
Occlusion Rule Do not bandage, cover, or wrap the treated skin area with an occlusive dressing unless explicitly directed by a physician.
Restricted Areas Do not apply to the face, axillae (underarms), or groin areas.
Missed Dose If a dose is missed, apply it as soon as it is remembered. If it is almost time for the next scheduled dose, skip the missed dose and return to the regular dosing schedule; do not apply two doses at once.

Procedural Summary

The established protocol requires washing hands before and after application. The medication must be applied only to the affected areas as a thin layer and gently rubbed in. The treatment is non-occlusive, meaning the treated area must not be covered unless a physician specifically instructs otherwise. The strict limits on the maximum weekly quantity and the short treatment duration define the structured approach to using this high-potency topical medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trials: Investigation in Chronic Pain

Studies evaluated whether the co-administration of Agent X and Drug Y was associated with changes in pain management for individuals reporting chronic back pain.

These trials utilized a randomized, double-blind, placebo-controlled design. The participant group was primarily composed of adults (aged 18–65) who had experienced chronic back pain for at least six months prior to enrollment.

  • Primary Outcome: The main measure evaluated was the change in pain intensity reported on the Visual Analog Scale (VAS) after 12 weeks of assessment.
  • Assessment Timepoint: One trial recorded the 6-week assessment as the point of greatest divergence from baseline.
  • Biological Basis: This section heading refers to the biological basis explored by researchers.

Subgroup Analysis and Co-Intervention

Some studies explored the effect of combining this treatment approach with physical therapy. The research also included a subgroup analysis to investigate differences in outcomes based on participant age and the duration of chronic pain.

  • Combined Agent Comparison: Some studies compared outcomes achieved with the combination versus either agent used individually.
  • Severe Symptom Management: Clinical trials explored the use of this approach in managing severe symptoms.
  • Trial Exclusion Criteria: One study noted that individuals with pre-existing heart conditions were excluded from participation.

Pediatric Research Status

Data regarding the co-administration of Agent X and Drug Y in pediatric participants remains limited, as trials predominantly focused on adult populations. Further research is required to evaluate potential findings and safety profiles in patients under 18 years of age.

Frequently Asked Questions (FAQ)

Common questions about Clonaderm (FAQ)

Q: Can I stop taking Clonaderm if I start feeling better?

A: Stopping Clonaderm suddenly is generally not recommended, even if symptoms appear to improve. Abrupt discontinuation may potentially lead to withdrawal symptoms or a return of the underlying condition.

A healthcare provider can offer guidance on a gradual dose reduction schedule, if appropriate. Regarding effectiveness, some people may start noticing improvement within a few weeks, though individual results and timelines can vary.

Q: What happens if I miss a dose of Clonaderm?

A: Specific instructions for a missed dose are usually detailed in the official product label or provided by your prescriber. These instructions typically advise taking the missed dose as soon as it's remembered, unless it is close to the time of the next scheduled dose.

In all cases, it is important to follow your healthcare provider's or pharmacist's specific advice. Using reminders can help maintain a consistent dosing schedule.

Q: Is Clonaderm safe to take during pregnancy?

A: Clonaderm's use during pregnancy involves balancing potential risks and benefits, as is the case with many medications. Research on its effects during pregnancy can vary, and data may be limited or inconclusive.

It is important to discuss the potential risks and benefits with a healthcare provider. A healthcare professional is the best source to evaluate if the potential benefits of taking Clonaderm outweigh the potential risks to the developing baby in an individual case.

How should Clonaderm be stored and disposed of?

How to Store and Dispose of Clonaderm?

Official regulatory guidelines define specific conditions for storing and discarding Clonaderm (Clobetasol Propionate) to maintain its integrity and ensure safety.

Official Storage Requirements

Clonaderm must be stored at controlled room temperature, typically 20 C to 25 C. It is mandatory to keep the medication out of the sight and reach of children and to store it in its original, tightly closed container. The product must be protected from freezing and excessive heat or moisture.

Handling and Disposal

For certain flammable formulations, such as foams or solutions, the product must be kept away from fire or flame. Stability rules for some creams mandate use within 28 days after the tube is opened. Unused or expired medication must be disposed of according to local regulations; it should not be thrown into household trash or poured down the drain to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

Equivalent of Clonaderm found in:

A-Z Index: